How one integrated laboratory test can detect both molecular and cytogenetic driving alterations across blood cancers

In this GLGC 2025 session, Laura Semenuk discusses how a SureSeq myPanel™ custom NGS cancer panel – the Somatic Myeloid Lymphoid Panel – was used as a solution to resolve the driver complexity found in myeloid and lymphoid neoplasms.

The results of this study found that that the Somatic Myeloid Lymphoid Panel delivered:

• Increased test efficiency:
• Identification of complex variants
• Confirmation of molecular remission status
• Integration of comprehensive patient results